KLKB1
Plasma kallikrein
As of the edition of 20 October 2026, KLKB1 (plasma kallikrein, UniProt P03952) has 8 drugs tested at it and 7 companies on the list, 0 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P03952
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 22
- Disease areas
- Heart and blood vessels; Skin and connective tissue; Immune system; Inherited and neonatal; Lungs and airways; Infections; Eye; Nervous system
- Registered trials of its drugs
- 93
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lanadelumab | Marketed | Phase 4 | Ends 2030 |
| Human c1-esterase inhibitor | Marketed | Phase 4 | Ended 2025 |
| Aprotinin | Marketed | Phase 4 | Ended 2005 |
| Berotralstat | Marketed | Phase 3 | Ends 2039 |
| Ecallantide | Marketed | Phase 3 | Ended 2021 |
| Sebetralstat | Marketed | Phase 4 | Ends 2037 |
| Avoralstat | Stopped | Phase 3 | none listed |
| KVD001 | Went quiet | Phase 2 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 6 |
| Undetermined | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| BioCryst Pharmaceuticals | Route B |
| Takeda | Route B |
| BioCryst | Route B |
The other 4 companies at KLKB1
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at KLKB1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.